Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma in the Bone Marrow
- 1 June 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 143 (6), 797-806
- https://doi.org/10.1309/ajcp6zodwv1cidme
Abstract
Objectives: The differential diagnosis between bone marrow involvement by lymphoplasmacytic lymphoma (LPL) and marginal zone lymphoma (MZL) is challenging because histology and immunophenotype of both diseases overlap. We revisited the diagnostic pathology features of both diseases in the bone marrow. Methods: We studied a series of bone marrow trephine biopsy specimens from 59 patients with Waldenström macroglobulinemia without extramedullary involvement and bone marrow biopsy specimens from 23 patients with well-characterized MZL who also had bone marrow involvement. H&E- and immunoperoxidase-stained sections of bone marrow trephine biopsy specimens as well as flow cytometry and classic cytogenetics performed on aspirations were reviewed. The study was complemented with MYD88 L265P mutation analysis of all samples. Results: The most distinguishing features of LPL with respect to MZL were focal paratrabecular involvement (P < .001), the presence of lymphoplasmacytoid cells (P < .001) and Dutcher bodies (P < .001), increased numbers of mast cells (P < .001), and the MYD88 L265P mutation (P < .001). Conclusions: LPL can be reliably distinguished from MZL in the bone marrow by using a combination of pathology characteristics. Our findings stress the diagnostic importance of using the combination of the following parameters for a correct LPL diagnosis: paratrabecular infiltration, the presence of lymphoplasmacytoid cells and cells with Dutcher bodies, and an increased number of mast cells in addition to the presence of MYD88 mutation.Keywords
This publication has 25 references indexed in Scilit:
- Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and managementAmerican Journal of Hematology, 2013
- MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reactionBlood, 2013
- MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemiaLeukemia, 2013
- MYD88 L265P Somatic Mutation in Waldenström's MacroglobulinemiaThe New England Journal of Medicine, 2012
- EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesLeukemia, 2012
- Lymphoplasmacytic Lymphoma and Other Non–Marginal Zone Lymphomas With Plasmacytic DifferentiationAmerican Journal of Clinical Pathology, 2011
- Waldenström macroglobulinaemiaBritish Journal of Haematology, 2007
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Waldenström's macroglobulinemia*Cancer, 1998
- Incipient myelomatosis or «essential« hyperglobulinemia with fibrinogenopenia — a new syndrome?Acta Medica Scandinavica, 1944